Stockreport

Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data [Yahoo! Finance]

Context Therapeutics Inc.  (CNTX) 
PDF solid tumors , advancing three programs—Claudin-6 and mesothelin in clinic and nectin-4 entering the clinic—while expecting Claudin-6 Phase 1a data in Q2 and mesothelin [Read more]